Severe infliximab‐induced psoriasis treated with adalimumab switching

BACKGROUND: Antitumor necrosis factor (anti-TNF) agents are a well-established treatment for various medical conditions, including psoriasis and psoriatic arthritis. However, anti-TNF agents may themselves induce psoriasis in some patients. METHODS: The authors report two cases of patients with severe and refractory infliximab-induced psoriasis. RESULTS: The patients had good clinical responses after switching to another TNF blocker. CONCLUSION: For severe cases, infliximab withdrawal combined with conventional immunosuppressive psoriasis drugs or with adalimumab may be a therapeutic option.